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Abstract
The Fc region of Immunoglobulin G (IgG) initiates inflammatory responses such as antibody-
dependent cell-mediated cytotoxicity (ADCC) through binding to activating Fc receptors (FcγRI, 
FcγRIIa, FcγRIIIa). These receptors are expressed on the surface of immune cells including 
macrophages, dendritic cells, and natural killer cells. An inhibitory receptor, FcγRIIb, is expressed 
on macrophages and other myeloid leukocytes simultaneously with the activating receptor 
FcγRIIa, thereby setting a threshold for cell activation. The affinity of IgG Fc for binding 
activating Fc receptors depends on IgG subclass and the composition of N-linked glycans attached 
to a conserved asparagine in the Fc CH2 domain. For example, Fc regions with afucosylated 
glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced 
ADCC activity in vivo and in vitro. Enhanced pro-inflammatory responses have also been seen for 
Fc regions with amino acid substitutions. GASDALIE Fc is an Fc mutant (G236A/S239D/A330L/
I332E) that exhibits a higher affinity for FcγRIIIa and increased effector functions in vivo 
compared to wild-type Fc. To explore its altered functions, we compared the affinities of 
GASDALIE and wild-type Fc for activating and inhibitory FcγRs. We also determined the crystal 
structure of GASDALIE Fc alone and bound to FcγRIIIa. The overall structure of GASDALIE Fc 
alone was similar to wild-type Fc structures, however, increased electrostatic interactions in the 
GASDALIE Fc:FcγRIIIa interface compared with other Fc:FcγR structures suggest a mechanism 
for the increased affinity of GASDALIE Fc for FcγRIIIa.
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Introduction
Immunoglobulin G (IgG) plays critical roles in antibody-mediated immune responses 
through specific engagement of both antigens and immune effector cells. The fragment 
crystallizable (Fc) region specifically engages Fc gamma receptors (FcγRs), the initial step 
in effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and 
antibody-dependent cellular phagocytosis (ADCP) (Arnold et al., 2007). In humans, 
activating FcγR FcγRIIIa (CD16) is expressed on the surface of natural killer cells and 
monocytes while FcγRIIa (CD32) is found on a wider range of innate immune cells 
including macrophages, dendritic cells, and neutrophils (DiLillo and Ravetch, 2015b; 
Richards et al., 2008). Both are low-affinity receptors, therefore activation of cells results 
from crosslinking of these surface receptors upon engagement of clustered Fc regions in 
antibody-antigen immune complexes (ICs) (Nimmerjahn and Ravetch, 2008). Activation is 
mediated by immunoreceptor tyrosine-based activating motifs (ITAMs) found on the 
receptor-associated γ-chain. Upon engagement of ICs with FcγRs, these motifs become 
phosphorylated leading to a cascade of events that activate the cell to destroy an invading 
pathogen or infected cell (Nimmerjahn and Ravetch, 2008). An inhibitory receptor, FcγRIIb, 
is found on cells including B cells, macrophages, neutrophils, and mast cells (Hulett and 
Hogarth, 1994; Ravetch and Bolland, 2001; Ravetch and Kinet, 1991). Immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic tail of FcγRIIb mediate 
suppression of FcγR activation by activating phosphatases that reverse the effects of kinases 
in the ITAM signaling pathway (Nimmerjahn and Ravetch, 2008). Co-expression of 
activating and inhibitory receptors sets a threshold for activation of specific effector cells.
IgG Fc regions are independently-folded, stable homodimers comprising two N-terminal 
hinges (each connected to an antigen-binding Fab arm) followed by two Ig constant 
domains, CH2 and CH3, on each chain of the homodimer. FcγRs bind asymmetrically to Fc 
homodimers with 1:1 receptor:Fc stoichiometry to a site involving the hinge region and N-
terminal portions of the CH2 domains (Ferrara et al., 2011). The Fc region includes a 
heterogeneous N-linked glycan attached to a conserved residue, Asn297, in each Fc CH2 
domain. The Asn297-linked glycan is a complex carbohydrate composed of a mannose 
(Man) and N-acetylglucosamine (GlcNAc) core that is usually fucosylated. The glycan can 
be additionally modified with a terminal galactose or sialic acid. Typically, wild-type (wt) 
IgG is agalactosylated (G0; 35%), mono-galactosylated (G1; 35%), or digalactosylated (G2; 
16%) and asialylated (S0; 85%), although mono- and disialylated IgG represent 11% and 
4%, respectively, of IgG in human serum (Butler et al., 2003). Modification of the N-linked 
glycan of IgG Fc can alter its function. For example, terminally sialylating the glycan 
switches the Fc from a pro-inflammatory to anti-inflammatory molecule (Anthony et al., 
2011; Anthony et al., 2008a; Anthony and Ravetch, 2010; Anthony et al., 2008b; Kaneko et 
al., 2006; Nimmerjahn and Ravetch, 2008; Samuelsson et al., 2001; Sondermann et al., 
2013), which may correlate with increased conformational flexibility compared with wtFc 
regions (Ahmed et al., 2014). Afucosylation of the normally core-fucosylated glycan leads 
to enhanced binding to the activating receptor FcγRIIIa, resulting in enhanced ADCC 
(Ferrara et al., 2011; Matsumiya et al., 2007; Mizushima et al., 2011; Okazaki et al., 2004) 
due to increased protein-protein and protein-carbohydrate interactions between the Fc and 
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receptor (Ferrara et al., 2011; Matsumiya et al., 2007; Okazaki et al., 2004). Removing the 
N-linked glycan leads to a closed Fc conformation that exhibits no binding to any FcγR 
(Shields et al., 2001); however, aglycosylated Fc can bind the FcRn protection receptor 
(Shields et al., 2001), which recognizes the interface between the CH2 and CH3 domains of 
each Fc chain (Burmeister et al., 1994), a site distant from the Asn297-linked N-linked 
glycan.
Previous efforts were made to alter the IgG Fc region to either enhance or suppress binding 
to FcγRs (Bournazos et al., 2014a; Duncan et al., 1988; Ferrara et al., 2011; Lazar et al., 
2006; Lin et al., 2015; Matsumiya et al., 2007; Nimmerjahn and Ravetch, 2008; Oganesyan 
et al., 2008a; Oganesyan et al., 2008b; Richards et al., 2008; Sazinsky et al., 2008; Shields et 
al., 2001). In a 2006 study, IgG Fc with mutations S239D/I332E (SDIE) or S239D/A330L/
I332E (SDALIE) showed enhanced ADCC and increased affinity for binding to 
FcγRIIIaF158 (30- and 60-fold for SDIE Fc and 60- and 170-fold for SDALIE Fc) (Lazar et 
al., 2006). In a separate study, SDIE Fc showed a 30-fold increased affinity for 
FcγRIIIAF158 (Smith et al., 2012). SDIE and SDALIE Fc also showed increased binding to 
the inhibitory receptor, FcγRIIb, by 70-fold and 40-fold, respectively (Lazar et al., 2006; 
Oganesyan et al., 2008a; Smith et al., 2012). A later study reported only a 14-fold increased 
affinity for SDIE binding to FcγRIIb (Smith et al., 2012). The crystal structure of unbound 
SDALIE Fc revealed a more open conformation compared with wtFc structures, but no 
major changes in the FcγR recognition interface (Oganesyan et al., 2008a). Related Fc 
mutants also showed increased activity and affinity for binding to FcγRs. A single G236A 
substitution in Fc showed 7-fold enhanced binding to FcγRIIa and enhanced phagocytosis in 
vitro, while an Fc with mutations G236A/S239D/I332E (GASDIE) exhibited a 70-fold 
phagocytosis enhancement (Richards et al., 2008). The G236A substitution alone did not 
cause enhanced binding to FcγRIIb, whereas the GASDIE mutant showed 14-fold enhanced 
affinity for this inhibitory receptor (Richards et al., 2008). GASDALIE Fc, a variant of 
SDALIE Fc that combined the G236A substitution with the SDALIE substitutions (G236A/
S239D/A330L/I332E), showed increased affinity for activating receptor FcγRIIIaF158 by 
20–30-fold (Bournazos et al., 2014b; DiLillo and Ravetch, 2015a; Smith et al., 2012). 
Unlike SDALIE Fc, GASDALIE Fc did not exhibit a large increase in affinity for the 
inhibitory receptor FcγRIIb (only a 2–3–fold increase for GASDALIE, as compared with a 
40-fold increase for SDALIE), (Bournazos et al., 2014b; DiLillo and Ravetch, 2015a; Smith 
et al., 2012).
IgGs with the GASDALIE mutations have recently been shown to exhibit increased 
protection in animal models of cancer and infectious disease (Bournazos et al., 2014b; 
DiLillo and Ravetch, 2015a; Smith et al., 2012). Although affinities of GASDALIE and 
SDALIE Fcs have been measured for some of the FcγRs (Bournazos et al., 2014a; 
Bournazos et al., 2014b; DiLillo and Ravetch, 2015a; Oganesyan et al., 2008a; Richards et 
al., 2008; Sazinsky et al., 2008; Smith et al., 2012), they have not been directly compared in 
a single experiment. In addition, there are discrepancies in reported affinities of Fc mutants 
for activating and inhibitory FcγRs (Bournazos et al., 2014a; Bournazos et al., 2014b; 
DiLillo and Ravetch, 2015a; Richards et al., 2008; Sazinsky et al., 2008; Smith et al., 2012). 
Here we directly compared binding of GASDALIE and SDALIE Fc to FcγRs, finding that 
Ahmed et al. Page 3
J Struct Biol. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
both Fcs exhibited large affinity increases for FcγRIIIa compared to wtFc, that GASDALIE 
exhibited a moderate affinity increase for FcγRIIa compared with wtFc, and that both Fcs 
showed only ~5-fold enhanced affinity for the inhibitory FcγRIIb receptor compared to 
wtFc. In order to determine the mechanism by which the GASDALIE substitutions 
enhanced binding to activating FcγRs, we solved crystal structures of GASDALIE Fc alone 
and in complex with FcγRIIIa, comparing the bound and free GASDALIE Fc structures to 
the previously-solved unbound SDALIE Fc structure (Oganesyan et al., 2008a; Smith et al., 
2012) and other Fc structures. We find that the GASDALIE substitutions did not 
dramatically alter the overall Fc conformation; however, the GASDALIE Fc:FcγRIIIa 
structure revealed increased electrostatic interactions at the binding interface that may 
account for its increased affinity for FcγRIIIa when compared to wtFc structures. Our 
GASDALIE Fc:FcγRIIIa crystal structure, homology models of GASDALIE Fc bound to 
FcγRIIa, and affinity measurements suggested that the G236A substitution that distinguishes 
GASDALIE Fc from SDALIE Fc is localized in the FcγRIIa binding site, thereby enhancing 
binding of FcγRIIa to GASDALIE compared with binding to wtFc or SDALIE Fc.
Materials and Methods
Protein Expression and Purification
The S239D/A330L/I332E (SDALIE) and G236A/S239D/A330L/I332E (GASDALIE) 
mutations were introduced by site-directed mutagenesis in a pcDNA3.1 vector containing 
the IgG1 Fc gene (Agilent Technologies). A plasmid containing the GASDALIE mutations 
(G236A/S239D/A330L/I332E) introduced into Fc region of the gene encoding the heavy 
chain of an anti-HIV-1 antibody, 3BNC117, was the gift of Stylianos Bournazos and Jeffrey 
Ravetch (Rockefeller University) (Bournazos et al., 2014b; Scheid et al., 2011). IgG and Fc 
proteins were expressed in transiently-transfected HEK 293-6E cells and purified from 
harvested supernatants using protein A chromatography (GE Healthcare) followed by size 
exclusion chromatography in 25 mM Tris-Cl pH 7.5, 100 mM NaCl on a Superdex 200 
10/300 gel-filtration column (GE Healthcare) as described (Diskin et al., 2010; Sprague et 
al., 2004). The Fc region from 3BNC117 IgG was isolated after papain digestion of 
3BNC117 GASDALIE IgG as described (Ahmed et al., 2014) and used for crystallization of 
GASDALIE Fc alone; other experiments used GASDALIE Fc expressed as an Fc fragment.
Expression plasmids encoding the F158 variant of FcγRIIIa and the H131 variant of FcγRIIa 
(FcγRIIIaF158 and FcγRIIaH131) were obtained from Stylianos Bournazos and Jeffrey 
Ravetch (Rockefeller University) (Bournazos et al., 2014b). Site directed mutagenesis was 
used to remove three of five potential N-linked glycosylation sites on FcγRIIIa (Asn38, 
Asn74, Asn169) by changing asparagines to glutamines to make N38Q, N74Q, N169Q 
substitutions, as described for previous structural studies of FcγRIIIa (Ferrara et al., 2011). 
Potential N-linked glycosylations sites at sites 45 and 162 were retained due to their effects 
on protein expression and binding affinity, respectively (Ferrara et al., 2011; Ferrara et al., 
2006). C-terminally 6x-His tagged FcγR ectodomains FcγRIIaH131 (residues 1–211) and 
FcγRIIIaF158 (residues 1–218) were expressed in transiently-transfected HEK293 cells as 
described for Fc proteins and isolated from supernatants using a HisTrap HP affinity column 
(GE Healthcare) followed by size exclusion chromatography in 25 mM Tris-Cl pH 7.5, 100 
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mM NaCl on a Superdex 200 16/ 60 gel-filtration column (GE Healthcare). To reduce 
carbohydrate heterogeneity that might impede crystallization, 2.5 μM kifunensine was added 
immediately before transfection of cells to inhibit processing of high-mannose N-linked 
glycans to their complex forms (Edberg and Kimberly, 1997).
Conventional SPR experiments
Biacore assays were performed on a Biacore T200 instrument. Proteins were immobilized 
on a CM5 sensor chip using primary amine coupling chemistry (amine-coupling wizard 
routine in the Biacore T200 software). Briefly, 1 μM FcγRIIIaF158, FcγRIIaH131, or FcγRIIb 
in 10 mM sodium acetate buffer at pH 5.0 or pH 4.5 were coupled at a flow rate of 1 μL/
minute for 420 seconds followed by ethanolamine coupling to block excess reactive 
carboxyl groups on the sensor chip surface. The coupling density was equivalent to 3162 RU 
for FcγRIIIaF158, 1840 RU for FcγRIIaH131, and 1516 RU for FcγRIIb. Flow channel 1 
served as the blank reference channel for bulk refractive index subtraction. Serial dilutions 
starting at a concentration of 10,000 nM of wtFc, SDALIE Fc, or GASDALIE Fc in 
HBSEP+ buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% (v/v) surfactant 
P20, pH 7.4) were injected at a flow rate of 30 μL/minute at 25 °C followed by a 200 second 
dissociation phase during which only HBSEP+ buffer was injected. 10 mM glycine pH 3 at 
30 μL/minute for 30 seconds was used for regeneration.
Sensorgrams were globally fitted to a 1:1 binding model using nonlinear regression in the 
Biaevaluation software. The fits were evaluated by plotting residuals between modeled and 
experimental curves. For comparisons with previously reported affinity measurements 
(Bournazos et al., 2014a; Bournazos et al., 2014b; Bruhns et al., 2009; DiLillo and Ravetch, 
2015a; Janeway et al., 2005; Lazar et al., 2006; Smith et al., 2012), KD values derived from 
these experiments are reported in Table 1 as conventional measurements and are calculated 
from the ratio of the kinetic constants as KD = kd/ka.
Competition SPR experiments
Competition SPR measurements were performed using methods similar to previously-
reported competition Biacore studies (Nieba et al., 1996). Flow cell 1 (ethanolamine blank) 
and flow cell 2 (FcγRIIIaF158) from the CM5 sensor chip used in the conventional SPR 
experiments were used for competition Biacore experiments. All measurements were carried 
out at 25 °C and a flow rate of 10 μL/minute and an injection time period of 120 seconds 
using HBSEP+ buffer. The chip was regenerated by injecting 10 mM glycine pH 3 at 30 μL/
minute for 30 seconds. Each experimental cycle evaluating the binding of an Fc protein to a 
receptor consisted of (i) Establishing a calibration curve to correlate the SPR response for 
each Fc protein binding to immobilized FcγRIIIaF158 as a function of concentration. For the 
calibration measurements, 2-fold dilution series of the Fc proteins including a no-protein 
standard (HBSEP+ buffer only) were used starting at the following concentrations: 803 nM 
(wtFc), 8 nM (SDALIE Fc), 5 nM (GASDALIE Fc). (ii) A measurement series evaluating 
the binding of an Fc protein to immobilized FcγRIIIaF158 in the presence of varying 
concentrations of competing FcγR in solution. For these measurements, a given Fc protein at 
a fixed concentration was first incubated for three hours with a 2-fold dilution series of a 
competitor receptor in solution. For wtFc injections, the concentration of wtFc was 401.5 
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nM and the competitor dilution series starting concentrations were 1396 nM (FcγRIIIaF158), 
1692 nM (FcγRIIaH131), and 1756 nM (FcγRIIb). For SDALIE Fc injections, the 
concentration of SDALIE Fc was 4 nM and the competitor dilution series starting 
concentrations were 87 nM (FcγRIIIaF158), 1692 nM (FcγRIIaH131), and 3512 nM 
(FcγRIIb). For GASDALIE Fc injections, the concentration of GASDALIE Fc was 2.5 nM 
and the competitor dilution series starting concentrations were 44 nM (FcγRIIIaF158), 846 
nM (FcγRIIaH131), and 3512 nM (FcγRIIb).
Data were analyzed using the Biacore T200 Evaluation software version 3.0. For the 
calibration curve, a 4-parameter fitting function was used. For calculation of the KD, the 
software uses a non-linear regression fit to the following function:
where variable Atot refers to the total concentration of the receptor in the Fc:FcγR mixture, 
Bfree refers to the concentration of the unbound Fc, and Btot refers to the total concentration 
of Fc in the mixture.
All curves were generated using the bulk refractive index subtracted response after an 
optimal injection time of 35 seconds (wtFc) or 144 seconds (SDALIE and GASDALIE Fc).
Crystallization
Crystals of GASDALIE Fc (space group P212121; a = 49.32 Å, b = 79.13 Å, c = 137.62 Å; 
one Fc dimer per asymmetric unit) were grown in sitting drop vapor diffusion by mixing 
equal volumes of GASDALIE Fc (7.36 mg/ml) with a solution containing 0.2 M ammonium 
formate and 20% (w/v) PEG 3350 at 20°C. Crystals were cryopreserved in well solution 
supplemented with 30% glycerol. Crystals of the GASDALIE Fc:FcγRIIIaF158 complex 
(space group P212121; a = 74.38 Å, b = 94.50 Å, c = 108.67 Å; one complex per asymmetric 
unit) were grown in sitting drop vapor diffusion by mixing equal volumes of protein (10 
mg/ml) with a solution containing 0.04 M potassium dihydrogen phosphate and 16% (w/v) 
PEG 8000 at 20°C. The complex crystals were cryopreserved in well solution.
Data Processing and Structure Determination
Data were collected to 2.4 Å resolution (GASDALIE Fc alone) and 3.1 Å resolution 
(Fc:FcγRIIIaF158 complex) at beamline 8.2.1 of the Advanced Light Source (ALS) at 
Lawrence Berkeley National Laboratory. Diffraction data were processed, indexed, 
integrated and scaled using iMosflm (Leslie and Powell, 2007) POINTLESS and SCALA, 
respectively (Evans, 2006; Evans, 2011). To determine the high-resolution cutoff for 
datasets, we used I/σI ratios and completeness of the highest resolution shell in addition to 
the criterion that the CC1/2 statistic (correlation coefficient between two random halves of a 
data set) should be greater than 10% (Karplus and Diederichs, 2012). We used Phenix 
(Adams et al., 2010) to compute CC1/2 values. Structures were solved by molecular 
replacement using PHASER (McCoy et al., 2007) and published Fc and Fc:FcγRIIIa 
structures as search models (PDB codes 3DO3 and 3SGK). Modeling was done using 
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COOT (Emsley et al., 2010). Crystallographic refinement was done using the Phenix 
crystallography package (Adams et al., 2010) by refining individual B factors for 
GASDALIE Fc and group B factors for the lower-resolution GASDALIE Fc:FcγRIIIaF158 
structure. We used PyMol (Schrödinger, 2011) for superposition calculations and molecular 
representations. Protein interfaces, surfaces and assemblies’ service PISA at the European 
Bioinformatics Institute (Krissinel and Henrick, 2007) was used to determine hydrogen 
bonding and electrostatic interactions at the GASDALIE Fc:FcγRIIIaF158 interface.
The GASDALIE Fc model (Rfree = 25.6%; Rwork = 23.5%) included 416 protein residues in 
the GASDALIE Fc dimer (Leu235 – Ser444 on chain A and Gly237 – Ser444 on chain B), 
18 glycan residues (GlcNAc1-Gal6, Fuc12 on chain A and GlcNAc1-GlcNAc8, Fuc12 on 
Chain B), and 105 water molecules.
The GASDALIE Fc: FcγRIIIaF158 complex (Rfree = 29.6%; Rwork = 27.1%) included 417 
protein residues in the GASDALIE Fc dimer (Ala236-Ser444 on chain A and Ala236-
Leu443 on chain B), 17 Fc glycan residues (GlcNAc1-Gal6, Fuc12 on chain A and 
GlcNAc1-Gal6, Fuc12 on Chain B), 169 protein residues in the FcγRIIIaF158 ectodomain, 
and FcγRIIIaF158 glycans GlcNAc1 attached to Asn162 and GlcNAc1 attached to Asn45. 
Side chains were disordered for residues Lys246, Lys248, Glu258, Glu269, Asp270, 
Glu272, Glu294, Tyr300, Lys326, and Arg355 on chain A, Lys246, Gln419 and Ser442 on 
chain B in the GASDALIE Fc dimer. No electron density was observed for side chains 
Phe11, Leu48, Ile49, Glu68, Gln72, Lys101, Glu103, Thr116, Lys128, Lys 143, Arg155, 
Gln174 and residues Tyr33-Ser39 and Ser75-Leu78 in the FcγRIIIaF158 ectodomain.
Homology Modeling
We used Pymol (Schrödinger, 2011) to superimpose the D2 domains of FcγRIIa (3RY4) or 
FcγRIIb (2FCB) to the D2 domain of FcγRIIIa in the GASDALIE Fc:FcγRIIIaF158 complex 
and the wtFc:FcγRIIIaV158 complex (3SGJ) in order to generate homology models of 
GASDALIE Fc:FcγRIIa, GASDALIE Fc:FcγRIIb, wtFc:FcγRIIa, and wtFc:FcγRIIb. The 
D2 domain of FcγRIIIa in the wtFc:FcγRIIIaV158 structure was onto V158 superimposed the 
D2 domain in the GASDALIE Fc:FcγRIIIaF158 complex to generate a GASDALIE 
Fc:FcγRIIIaV158 homology model. PISA (Protein interfaces, surfaces and assemblies) 
service at the European Bioinformatics Institute (Krissinel and Henrick, 2007) was used to 
evaluate hydrogen bonding and electrostatic interactions at the GASDALIE 
Fc:FcγRIIIaV158, GASDALIE Fc:FcγRIIa and wtFc:FcγRIIa interfaces.
Results
Comparison of Affinities of Fc Variants for Activating and Inhibitory FcγRs
Activating FcγRs exist in variant forms in the human population depending on the amino 
acid identity at positions 158 (Phe158 or Val158 for FcγRIIIa) or 131 (His131 or Arg131 for 
FcγRIIa) (Ackerman and Nimmerjahn, 2014). The polymorphism at residue 158 of FcγRIIIa 
was reported to affect binding to Fcs: e.g., FcγRIIIaF158 exhibited an ~5-fold lower affinity 
for wtFc compared to FcγRIIIaV158 (Bournazos et al., 2014b); however, there was no 
interaction between residue 158 of FcγRIIIa and wtFc in the wtFc:FcγRIIIaV158 complex 
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structure (PDB 3SGJ). The histidine to arginine polymorphism at residue 131 of FcγRIIa did 
not affect binding to wtFc of human IgG1 (Bournazos et al., 2014b), although Arg131 of 
FcγRIIaR131 interacts with Fc in a wtFc:FcγRIIaR131 complex structure (PDB 3RY6). For 
our studies, we expressed the Phe158 and His131 forms of FcγRIIIa and FcγRIIa 
(FcγRIIIaF158 and FcγRIIaH131) for comparisons with previous in vitro and in vivo studies 
(Bournazos et al., 2014a; Bournazos et al., 2014b; DiLillo and Ravetch, 2015a; Oganesyan 
et al., 2008a; Richards et al., 2008; Sazinsky et al., 2008; Smith et al., 2012).
FcγR ectodomains, wtFc, and Fc variants were purified from supernatants of transiently-
transfected mammalian cells as previously described (Diskin et al., 2010; Sprague et al., 
2004). To attempt to resolve inconsistencies in the reported affinities of Fc mutants to FcγRs 
(Bournazos et al., 2014a; Bournazos et al., 2014b; Richards et al., 2008; Sazinsky et al., 
2008; Smith et al., 2012) (Table 1), we first directly compared the affinities of wtFc, 
SDALIE Fc and GASDALIE Fc for binding to immobilized FcγRIIaH131, FcγRIIb, or 
FcγRIIIaF158 using a surface plasmon resonance (SPR)-based binding assay in which 
equilibrium dissociation constants (KD values) were calculated by determining the ratio of 
kinetic constants based on global fits of the association and dissociation phases of 
sensorgrams. However, we found that the binding data could not be accurately modeled by a 
1:1 binding interaction (Fig. 1a). When we calculated KD values using the poorly-fit models, 
we obtained results similar to some of the previous reports that obtained affinities using a 
1:1 binding interaction to model Fc:FcγR sensorgrams involving Fcs injected over 
immobilized FcγRs (Bournazos et al., 2014a; Bournazos et al., 2014b; Bruhns et al., 2009; 
DiLillo and Ravetch, 2015a; Janeway et al., 2005; Smith et al., 2012) (Table 1). However, 
higher affinities were reported for methods that did not involve measurements of affinities 
for immobilized FcγRs: for example, competition Biacore measurements (Lazar et al., 2006) 
(Table 1) or conventional SPR experiments in which the affinity of an injected FcγR for 
immobilized Fc was derived (Oganesyan et al., 2008a; Richards et al., 2008). These results 
suggested the possibility of artifacts in experiments that derive affinities for direct 
interactions with immobilized FcγRs.
To obtain consistent and more accurate comparisons of affinities, we used a measurement 
method similar to competition Biacore (Nieba et al., 1996) in which affinities are derived for 
Fc:FcγR interactions in solution. In this method, an FcγR (FcγRIIIaF158 in our experiments) 
is immobilized on a sensor chip, and a constant concentration of Fc incubated with varying 
amounts of a soluble FcγR (either FcγRIIIaF158, FcγRIIaH131, or FcγRIIb) is injected over 
the sensor chip (Fig. 1b). Fc proteins that are bound to the FcγR in solution are unable to 
bind the immobilized receptor. By measuring the amount of Fc that binds to immobilized 
receptor, we can calculate the concentration of Fc bound to the soluble FcγR. As the 
concentration of soluble receptor is decreased, fewer FcγR interactions with Fc occur in 
solution, and more of the unbound Fc is available to bind to the immobilized receptor. This 
allows for correlation of the SPR signal generated from unbound Fc in solution with a signal 
derived from an independent calibration experiment recording SPR signals from a series of 
known Fc concentrations. The concentration values derived this way are used together with 
known concentrations of total Fc and soluble FcγR to calculate the KD for a given Fc:FcγR 
interaction. Because the KD values obtained using this method were higher than those 
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derived in our own (Table 1) and in others’ conventional SPR experiments (Bournazos et al., 
2014a; Bournazos et al., 2014b; Bruhns et al., 2009; DiLillo and Ravetch, 2015a; Smith et 
al., 2012), we present the results as the fold improvement in the affinity of the SDALIE or 
GASDALIE Fc for a given FcγR in Table 1 (i.e., KD of Fc mutant/KD of wtFc). Given the 
poor fits of models to the conventional SPR measurements (Fig. 1a) compared with the 
excellent fits for the competition-based experiments (Fig. 1b), we based our comparisons of 
wtFc:FcγR and mutant Fc:FcγR affinities on the competition-based experiments.
We found that both GASDALIE and SDALIE Fc bound to FcγRIIIaF158 with approximately 
the same increased affinity compared with wtFc (431-fold and 318-fold increases for 
GASDALIE and SDALIE, respectively) (Table 1). GASDALIE Fc bound to FcγRIIaH131 7-
fold more tightly than did SDALIE Fc, with GASDALIE Fc showing 17-fold increased 
affinity for FcγRIIaH131 compared to wtFc, but SDALIE Fc and wtFc showing 
approximately the same affinity for FcγRIIaH131 (within ~2-fold). Both GASDALIE Fc and 
SDALIE Fc had a similar increase in binding to the inhibitory receptor FcγRIIb when 
compared to wtFc (5–6-fold). Although GASDALIE Fc and SDALIE Fc showed similar 
binding to FcγRIIIaF158 and FcγRIIb, the additional G236A mutation (GA in GASDALIE) 
further enhanced the affinity of GASDALIE Fc for FcγRIIaH131 when compared to SDALIE 
Fc (Table 1).
Crystal Structure of GASDALIE Fc Bound to FcγRIIIa
To facilitate crystallization of the GASDALIE Fc:FcγRIIIaF158 complex, three of five 
potential N-linked glycosylation sites on FcγRIIIaF158 were removed by site directed 
mutagenesis (N38Q, N74Q, N169Q). N-linked glycans at asparagines 45 and 162 were 
retained due to their effects on protein expression and Fc binding affinity, respectively 
(Ferrara et al., 2011; Ferrara et al., 2006). The complex structure was solved by molecular 
replacement using an afucosylated Fc:FcγRIIIa complex structure (PDB 3SGK) as a search 
model and refined to 3.1 Å (Rcryst = 0.27; Rfree = 0.29) (Supplementary Table 1). N-linked 
glycans were built into electron density up to a terminal galactose on the 6-arm and up to a 
terminal GlcNAc on the 3-arm of Fc chains A and B (Supplementary Fig. 1a). On 
FcγRIIIaF158, ordered electron density was observed for a GlcNAc attached to Asn45 and 
for a GlcNAc attached to N162 (Supplementary Fig. 1b). The sites of the GASDALIE 
substitutions (positions 236, 239, 330, and 332) were visible in ordered electron density on 
Fc chains A and B (Supplementary Fig. 1c).
Similar to previous structures of Fc:FcγR complexes (Ferrara et al., 2011; Matsumiya et al., 
2007; Mizushima et al., 2011; Radaev et al., 2001), the GASDALIE Fc:FcγRIIIaF158 
structure revealed an asymmetric 1:1 interaction in which the region connecting 
FcγRIIIaF158 domains 1 and 2 (D1 and D2) together with D2 loops BC, C’E and FG 
interacted with the lower hinge region of Fc chains A and B and the CH2 domain BC, C’E 
and FG loops (Fig. 2a). Because the asymmetric binding of FcγRs to two-fold symmetric Fc 
regions results in different effects of the Fc substitutions on the two chains of the Fc 
homodimer, we will describe comparisons of the GASDALIE Fc:FcγRIIIaF158 and 
wtFc:FcγRIIIaV158 (PDB 3SGJ) structures separately for both Fc chains. Starting with the 
interactions of Fc chain A with FcγRIIIaF158, we found electrostatic interactions resulting 
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from one of the GASDALIE substitutions, S239D, in which a positively-charged residue, 
Lys120, in the BC loop of FcγRIIIaF158 D2 was positioned in a pocket between Fc chain A 
residues Asp239 (SD in GASDALIE) and Asp265 (Fig. 2b). By comparison, in the 
wtFc:FcγRIIIaV158 complex, Fc residue Ser239 formed a hydrogen bond with FcγRIIIa 
Lys120. The introduced residues Leu330 and Glu332, the AL and IE substitutions of 
GASDALIE, did not play a role in the interface of FcγRIIIaF158 with chain A of 
GASDALIE Fc. Ala236 (the GA substitution in GASDALIE Fc) also was not at the binding 
interface; however, Gly236 in the wtFc:FcγRIIIaV158 complex formed a hydrogen bond with 
His135 of FcγRIIIaF158 (Fig. 2b). The salt bridge formed by Asp239 on Fc chain A (SD 
substitution in GASDALIE Fc and SDALIE Fc) and Lys120 of FcγRIIIa, which is not seen 
in wtFc:FcγRIIIaV158 complex structures (Ferrara et al., 2011; Mimoto et al., 2013; 
Mizushima et al., 2011; Radaev et al., 2001; Sondermann et al., 2000), may contribute to the 
increased affinity of GASDALIE Fc for FcγRIIIa, whereas the additional mutations G236A, 
A330L, and I332E do not participate in the interaction between GASDALIE Fc chain A and 
FcγRIIIaF158.
On chain B of GASDALIE Fc, we found new interactions with the introduction of the 
GASDALIE substitutions that may also contribute to the enhanced affinity for FcγRIIIaF158 
of GASDALIE compared to wtFc (Bournazos et al., 2014b; Smith et al., 2012) (Table 1). 
Lys161 in the FG loop of FcγRIIIaF158 formed an electrostatic interaction with Fc chain B 
residue Glu332, the IE substitution in GASDALIE Fc, an interaction not seen in 
wtFc:FcγRIIIaV158 complex structures since Ile332 of wtFc did not interact with 
FcγRIIIaF158 Lys161 (Fig. 2c). Ala236, the GA substitution in GASDALIE Fc, makes a 
hydrophobic contact with FcγRIIIa residue Phe158; however, Fc residue Gly236 in the 
wtFc:FcγRIIIaV158 complex formed a hydrogen bond with Lys161 of the receptor and did 
not contact receptor residue 158. Asp239 and Leu330 (the SD and AL substitutions in 
GASDALIE) on chain B were not at the binding interface with the receptor. The salt bridge 
formed by Glu332 on Fc chain B (IE substitution in GASDALIE Fc and SDALIE Fc) and 
Lys161 of FcγRIIIaF158, and the hydrophobic interaction between Fc residue Ala236 and 
FcγRIIIa residue Phe158, which is not seen in wtFc:FcγRIIIaV158 complex structures (Fig. 
2c), may have contributed to the increased affinity of GASDALIE Fc to FcγRIIIa, whereas 
the additional mutations on chain B (S239D and A330L) did not participate in the interface.
Modeling of the interactions of GASDALIE Fc with FcγRIIa and FcγRIIb
To gain understanding of the enhanced affinity of GASDALIE Fc for FcγRIIa compared to 
SDALIE Fc and to wtFc (GASDALIE Fc binds FcγRIIa with 17-fold increased affinity 
compared with wtFc, whereas SDALIE Fc binds FcγRIIa with only 2-fold increased affinity 
compared with wtFc; Table 1 competition SPR results), we used homology modeling 
(Schrödinger, 2011) to create models of GASDALIE Fc:FcγRIIa, and wtFc:FcγRIIa 
complexes based on high-resolution structures of FcγRIIa (PDB 3RY4), the 
wtFc:FcγRIIIaV158 complex (PDB 3SGJ) and the GASDALIE Fc:FcγRIIIaF158 complex 
described in this study. We also created homology models of GASDALIE Fc:FcγRIIb and 
wtFc:FcγRIIb complexes using the FcγRIIb structure (PDB 2FCB) to look for a structural 
rationalization for the relatively small effect of the GASDALIE substitutions on Fc binding 
to the inhibitory FcγRIIb receptor (GASDALIE Fc and SDALIE Fc bind FcγRIIb with only 
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5–6–fold increased affinities compared with wtFc; Table 1 competition SPR results). The 
homology modeling was feasible because the Fc-binding D2 domains of FcγRIIa, FcγRIIb, 
and FcγRIIIa share sequence and structural homology (root mean square deviations, rmsds, 
ranging from 0.5 – 0.7 Å for pairwise combinations) (Fig. 3a,b) and bind to Fcs with similar 
orientations, as demonstrated by crystal structures (Ferrara et al., 2011; Maxwell et al., 
1999; Mimoto et al., 2013; Mizushima et al., 2011; Radaev et al., 2001; Ramsland et al., 
2011; Sondermann et al., 1999; Sondermann et al., 2000; Sondermann et al., 2001) and site-
directed mutagenesis studies (Maxwell et al., 1999; Mimoto et al., 2013; Ramsland et al., 
2011; Shields et al., 2001; Sondermann et al., 1999; Sondermann et al., 2001).
To validate the modeling methods, we first constructed a homology model of the 
GASDALIE Fc:FcγRIIIaF158 structure using the wtFc:FcγRIIIaV158 complex structure 
(PDB 3SGJ) as a starting reference. The GASDALIE Fc:FcγRIIIaF158 model exhibited a 1.2 
Å rmsd compared with the GASDALIE Fc:FcγRIIIaF158 crystal structure (calculated for all 
Cα atoms) and reproduced the interactions of the GASDALIE substitutions with 
FcγRIIIaF158. The relatively large rmsd for the superposition is explained by the flexibility 
and partial disorder of the D1 domain of FcγRIIIa, which does not contact Fc in Fc:FcγRIIIa 
complex structures (Ferrara et al., 2011; Mizushima et al., 2011; Radaev et al., 2001; 
Sondermann et al., 2000) (Fig. 2a). By comparison, the D2 domain in the modeled 
GASDALIE Fc:FcγRIIIaF158 complex exhibited a lower rmsd (0.4 Å; calculated for 72 Cα 
atoms) compared with the GASDALIE Fc:FcγRIIIaF158 crystal structure. Having validated 
the homology modeling procedure, we generated homology models for GASDALIE 
Fc:FcγRIIa, GASDALIE Fc:FcγRIIb, wtFc:FcγRIIa, and wtFc:FcγRIIb complex structures 
by aligning the D2 domain of FcγRIIa or FcγRIIb with D2 of FcγRIIIa in the appropriate 
Fc:FcγRIIIa complex structure.
Several interactions predicted by the GASDALIE Fc:FcγRIIa and wtFc:FcγRIIa homology 
models gave insight into the 17-fold increased affinity of GASDALIE Fc versus wtFc for 
FcγRIIa. On Fc chain A, Asp239 (SD in GASDALIE) and Asp265 were predicted to form 
electrostatic interactions with FcγRIIa Lys117 (the counterpart of FcγRIIIa Lys120) (Fig. 
3c, top left). Fc residue Asp265 may also hydrogen bond with FcγRIIa residue His131. By 
comparison, in the wtFc:FcγRIIa structure, Fc residue 239, a serine, did not contact FcγRIIa, 
although Fc residue Asp265 was predicted to form a salt bridge with FcγRIIa Lys117 and a 
hydrogen bond with FcγRIIa His131 (Fig. 3c, top right). Fc substitutions Leu330 and 
Glu332 (AL and IE in GASDALIE Fc) were not predicted to play a role in binding at the 
interface of FcγRIIa with GASDALIE Fc chain A. The effects of the GA substitution in 
GASDALIE Fc may be explained by a predicted hydrogen bond between GASDALIE Fc 
residue Ala236 (the site of the GA substitution) and FcγRIIa residue His131, whereas Fc 
residue Gly236 in wtFc is not predicted to interact with the FcγRIIa (Fig. 3c). Consistent 
with the similar binding affinities of GASDALIE Fc and wtFc for FcγRIIb (Table 1), the 
GASDALIE substitutions Ala236, Asp239, Leu330, and Glu332 in GASDALIE Fc chain A 
were not predicted to play a role at the binding interface with FcγRIIb in the GASDALIE 
Fc:FcγRIIb homology model (Fig. 3c, bottom left). Although FcγRIIa residue Lys117 was 
predicted to participate in electrostatic interactions and hydrogen bonding at the GASDALIE 
Fc:FcγRIIa interface, Lys117 of FcγRIIb was not predicted to interact with any of the Fc 
residues on chain A of either GASDALIE Fc or wtFc (Fig. 3c, bottom).
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On Fc chain B, residues Asp239 (the SD substitution of GASDALIE) and Asp265 are 
predicted to hydrogen bond with FcγRIIa residue Thr158 (Fig. 3d, top left). By comparison, 
if there is a serine instead of an aspartate at Fc position 239, as in wtFc, a hydrogen bond is 
predicted to form between the serine and FcγRIIa residue Tyr157 (Fig. 3d, top right). The 
remaining GASDALIE substitutions (GA, AL, and IE substitutions) are not predicted to 
play a role at the interface in this region. In the GASDALIE Fc:FcγRIIb model, Fc residue 
Ala236 (GA substitution) is predicted to hydrogen bond with FcγRIIb residues Tyr160 and 
possible also Thr158 (Fig. 3d, bottom left). If there is a glycine at Fc position 236 instead of 
an alanine, as in the wtFc, a hydrogen bond is predicted to form with FcγRIIb residue 
Tyr160 (Figure 3d, bottom right). Asp239, Leu330 and Glu332 (GASDALIE SD, AL, and 
IE substitutions) are not predicted to play a role at the GASDALIE chain B Fc interface with 
FcγRIIb. Thus the GASDALIE Fc substitutions in Fc chain B do not exert major effects on 
interactions with FcγRIIb. The addition of the G236A mutation is predicted to result in an 
increase of hydrogen bonding at the GASDALIE Fc:FcγRIIa interface but not at the 
GASDALIE Fc:FcγRIIb interface, which may explain the 7-fold increase in affinity for 
FcγRIIa of GASDALIE Fc when compared to SDALIE Fc, which lacks the GA substitution 
in GASDALIE Fc.
Conformations of free and receptor-bound GASDALIE Fc
In order to determine if unbound GASDALIE Fc exhibits conformational changes associated 
with its increased affinity for FcγRIIIaF158 compared with wtFc, we solved a 2.4 Å 
resolution crystal structure of GASDALIE Fc alone by molecular replacement (Rcryst = 0.24; 
Rfree = 0.26). The structure revealed a typical Fc homodimer with N-glycans attached to 
CH2 domain residue Asn297. Ordered electron density was observed up to a terminal 
galactose on the 6-arm and up to a terminal N-acetyl glucosamine on the 3-arm of the N-
linked glycan, as found in wtFc structures and the SDALIE Fc structure (Oganesyan et al., 
2008a). The SDALIE substitutions were located in ordered electron density; however, the 
region containing Ala236 (the GA substitution in GASDALIE) was disordered on both 
chains A and B (Supplementary Fig. 1d).
To assess potential differences between GASDALIE Fc and wtFc structures, the CH3 
domains of each Fc were aligned and the positions of the CH2 domains were compared 
(Figure 4a,b). We monitored CH2 domain separations in the various Fc structures by 
measuring distances between the Cα atoms at CH2 positions 238, 241, 301, and 329 as 
described (Ahmed et al., 2014; Teplyakov et al., 2013) (Figure 4c). As previously noted, 
wtFc structures exhibit relatively small structural differences, showing similar CH2 domain 
separations despite differences in crystal packing (Ahmed et al., 2014). The separation 
between the CH2 domains of GASDALIE Fc structure fell within range of CH2 domain 
separations in wtFc (PDB 3DO3, 2DTS, 3AVE, 1HZH and 4Q7D); therefore the 
GASDALIE mutations did not greatly influence the overall CH2-CH2 domain arrangement 
in the unbound structure (Fig. 4a; Table 2). We also aligned the CH3 domains of the 
unbound GASDALIE Fc structure with the CH3 domains of the 2.5 Å SDALIE Fc structure 
(PDB 2QL1) (Oganesyan et al., 2008a). SDALIE Fc was in a more open conformation than 
GASDALIE with an rmsd of 5.8 Å calculated for the 201 CH2 domain Cα atoms (Fig. 4a).
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We next compared the free GASDALIE Fc structure to the structure of GASDALIE solved 
in complex with FcγRIIIaF158. No notable differences were seen in side chain conformations 
at the sites of the GASDALIE mutations (Supplementary Fig. 1c.d). The CH2 domains of 
the bound GASDALIE Fc were in a more open conformation compared with the unbound 
form (Fig. 4b, Table 2) (rmsd of 2.3 Å calculated for the 202 Cα atoms of the CH2 domains 
of one Fc after alignment of the CH3 domains in each structure) and the FcγRIIIaF158-bound 
GASDALIE Fc fell within the range of CH2 domain separations for receptor-bound Fc 
structures (Fig. 4b; Table 2). This result was expected since previously solved complexes of 
afucosylated and fucosylated Fc bound to FcγRIIIa did not show major changes in overall 
Fc conformation (Ferrara et al., 2011; Sondermann et al., 2000).
Discussion
The effector functions of IgG can be modulated with glycan and protein modifications to its 
Fc region (Ackerman and Nimmerjahn, 2014). Here we examined the effects of introducing 
amino acid substitutions in the Fc CH2 domain, either G236A/S239D/A330L/I332E 
(GASDALIE) or S239D/A330L/I332E (SDALIE), which increase binding to activating 
FcγR receptors but exhibit relatively small affinity increases for the FcγRIIb inhibitory 
receptor (Bournazos et al., 2014a; Bournazos et al., 2014b) (Table 1). These effects lead to 
enhanced Fc-mediated effector functions, of importance for the efficacies of therapeutic 
antibodies against cancer and infectious diseases (Ferrara et al., 2011; Lazar et al., 2006; 
Matsumiya et al., 2007; Mizushima et al., 2011; Richards et al., 2008).
Previous SPR-based measurements to derive affinities of wtFc and mutant Fcs for FcγRs 
used a 1:1 (Langmuir) binding model to derive kinetic constants for the interactions of Fc 
proteins with immobilized receptors (Bournazos et al., 2014b; Lazar et al., 2006; Richards et 
al., 2008; Smith et al., 2012). Here we showed that sensorgrams of Fc binding to 
immobilized FcγRs do not fit a 1:1 binding model, and are therefore unlikely to result in 
reliable binding affinity constants (Fig. 1a). In order to avoid inaccuracies resulting from 
poorly fit models of Fc binding to immobilized receptors, we chose a measurement method 
based on equilibrium binding in solution to derive affinities for FcγRs binding to the 
GASDALIE and SDALIE Fcs (Fig. 1b). The method is based on concentration 
measurements of unbound ligands after equilibrium binding to their binding partner (Nieba 
et al., 1996); in this case, Fc binding to an FcγR. Concentrations of free ligand were 
determined using a calibration measurement series carried out in the same experiment. 
Using this method, we found that GASDALIE Fc and SDALIE Fc showed over two orders 
of magnitude of enhanced binding compared with wtFc to the activating Fc receptor 
FcγRIIIaF158, but only a 5–6-fold increase in binding to the inhibitory receptor FcγRIIb. 
GASDALIE Fc also exhibited increased binding (17-fold higher affinity) to FcγRIIa, 
whereas the affinities of SDALIE Fc and wtFc for FcγRIIa were similar (Table 1). Although 
our structural studies showed that the G236A substitution that distinguishes GASDALIE and 
SDALIE formed a hydrophobic contact with residue Phe158 of FcγRIIIaF158 in the 
GASDALIE Fc:FcγRIIIaF158 complex structure, it did not cause a difference in increased 
binding affinity between SDALIE Fc and GASDALIE Fc to FcγRIIIaF158 when compared 
to wtFc (Fig. 2; Table 1); however, homology modeling of a GASDALIE Fc:FcγRIIa 
complex suggested that GASDALIE Fc residue Ala236 could enhance binding of 
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GASDALIE Fc to FcγRIIa through increased H-bond interactions as compared with binding 
of SDALIE and wtFc (Fig. 3).
We used the GASDALIE Fc:FcγRIIIaF158 complex crystal structure to rationalize the 
increased affinities for activating FcγRs resulting from the GASDALIE substitutions. The 
structure revealed electrostatic interactions resulting from the interactions of negative 
charges introduced by the SD and IE GASDALIE substitutions with lysine residues in the 
receptor; e.g., the side chain of FcγRIIIa Lys120 extended into a pocket on Fc containing 
chain A residues Asp265 and Asp239 (SD in GASDALIE). Although not one of the 
GASDALIE substitutions, Fc residue Asp265 is important for interactions with FcγRs to 
mediate ADCC: when this residue was substituted for alanine, binding to both activating and 
inhibitory FcγRs was abrogated (DiLillo et al., 2014). The introduction of Asp239 (SD in 
GASDALIE and SDALIE) may further stabilize the Asp265Fc/Lys120FcγR interaction 
contributing to the higher than wtFc affinities of GASDALIE and SDALIE Fcs for FcγRIIIa. 
FcγRIIa also includes a lysine at position 120 predicted to form similar electrostatic 
interactions with Fc chain A Asp239 leading to an enhanced binding to activating FcγRs. 
Another receptor lysine, Lys161FcγRIIIa, formed an electrostatic interaction with 
GASDALIE Fc residue Glu332 (the IE portion of the GASDALIE substitutions), which 
cannot occur in wtFc containing an isoleucine at position 332. The greater increase in 
electrostatic interactions at the interface of GASDALIE Fc with FcγRIIIaF158 (GASDALIE 
Asp239 interactions with FcγRIIIaF158 Lys120 and GASDALIE Glu332 interactions with 
FcγRIIIaF158 Lys161) and FcγRIIa (GASDALIE Asp239 interactions with FcγRIIa Lys120) 
suggests that electrostatic interactions with receptor lysines are the main contributors in 
enhancement of GASDALIE Fc binding to activating receptors, with FcγRIIIa benefitting 
more than FcγRIIa from the SD and IE substitutions of GASDALIE Fc.
We also present the structures of GASDALIE Fc in its unbound state. Fc structures exhibit 
varying degrees of openness, as assessed by the separation of their CH2 domains (Ahmed et 
al., 2014; Ferrara et al., 2011; Mizushima et al., 2011; Oganesyan et al., 2008a; Radaev et 
al., 2001; Sondermann et al., 2001), although wtFc structures are relatively similar to each 
other (Ahmed et al., 2014). The GASDALIE Fc structure was similar to wtFc structures in 
that the separation of its CH2 domains fell within the range of CH2 domain separations in 
wtFc structures (Fig. 4A; Table 2). By contrast, the SDALIE Fc structure was in a more 
open conformation than wtFc structures (Oganesyan et al., 2008a). However, notable 
changes in the side chain conformations of the SDALIE substitutions were not observed 
when compared to GASDALIE Fc.
Conclusions
Here we present binding and structural data relevant to understanding the effects of the 
GASDALIE substitutions in Fc for its interactions with FcγRs. We found that both 
GASDALIE and SDALIE Fcs exhibited large increases in binding to activating FcγRs, most 
notably to FcγRIIIa. This property, when combined with their relatively small effects on 
binding to the inhibitory FcγRIIb receptor, is optimal for eliciting activation of FcγRIIIa- 
and FcγRIIa-expressing cells leading to ADCC. Further co-crystallization experiments with 
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both FcγRIIa and FcγRIIb and binding experiments with other Fc variants will be essential 
for further understanding how these mutations allow selection for activating Fc receptors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Stylianos Bournazos, John Desjarlais, and Jeffrey Ravetch for helpful discussions, the Caltech Protein 
Expression Center for protein production, members of the Bjorkman lab for critical reading of the manuscript, 
Marta Murphy for help making figures, and Jens Kaiser and members of the staff at the Advanced Light Source 
(ALS) for help with data collection and processing. The Advanced Light Source is supported by the Director, 
Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-
AC02-05CH11231. This research was supported by the National Institute Of Allergy And Infectious Diseases of 
the National Institutes of Health Grant HIVRAD P01 AI100148 (P.J.B.); (the content is solely the responsibility of 
the authors and does not necessarily represent the official views of the National Institutes of Health) and the 
Molecular Observatory at Caltech supported by the Gordon and Betty Moore Foundation.
Abbreviations
ADCC antibody-dependent cell-mediated cytotoxicity
ADCP antibody-dependent cellular phagocytosis
Fc fragment crystallizable
FcγR Fc gamma receptor
GlcNAc N-acetylglucosamine
KD equilibrium dissociation constant
IgG immunoglobulin G
IC immune complex
ITAM immunoreceptor tyrosine-based activating motif
ITIM immunoreceptor tyrosine-based inhibitory motif
SPR surface plasmon resonance
wt wild-type
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Figure 1. 
SPR binding assays of Fc:FcγR interactions. (a) Sensorgrams from conventional SPR 
experiments in which Fc proteins were injected over immobilized FcγRs. Experimental data 
(colored lines) were fit to a 1:1 binding model (black lines). Residual plots are shown below 
each set of sensorgrams. For most interactions, the association and/or dissociation phases of 
the sensorgrams do not fit a 1:1 binding model. In cases in which the association and 
dissociation rates are very fast, the 1:1 binding model appears to fit the sensorgrams, but the 
kinetic rate constants are outside of the detectable range of the instrument and the 
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equilibrium RU values do not converge as the concentration of analyte is raised. (b) 
Competition SPR results. Equilibrium binding curves for interactions of the Fc variants 
(wtFc, SDALIE Fc, and GASDALIE Fc) with Fcγ receptors (FcγRIIIa, FcγRIIa, and 
FcγRIIb). Each curve represents an equilibrium binding experiment in which the free Fc 
concentration (y-axis) is plotted versus the competitor (FcγR) concentration (logarithmic x-
axis). Data points (triangles, circles, or squares) were fit by non-linear regression to the 
second order root function to an equilibrium binding model (solid black line) as described in 
the Methods. The more a curve is shifted to the left, the stronger the Fc:FcγR binding (i.e., 
the higher the affinity).
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Figure 2. 
Structure of GASDALIE Fc:FcγRIIIaF158 complex. (a) Overview of the GASDALIE 
Fc:FcγRIIIaF158 complex. FcγRIIIaF158 is in pink ribbon representation and GASDALIE Fc 
is in blue ribbon representation with the G236/S239D/A330L/I332E mutations highlighted 
as red spheres and N-linked glycans shown as blue sticks. (b–c) Comparison of interfaces in 
the GASDALIE Fc:FcγRIIIaF158 and wtFc:FcγRIIIa structures on Fc chain A (panel b) and 
Fc chain B (panel c). Residues involved in interactions are shown in magenta (FcγRIIIa) and 
blue (Fc) with oxygen atoms in red and nitrogens in blue. Dotted lines between atoms 
represent lectrostatic interactions (red) or hydrogen bonds (yellow). Residues that do not 
participate in hydrogen bonds or electrostatic interactions are shown in gray.
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Figure 3. 
Comparison of the interfaces of FcγRIIa and FcγRIIb with GASDALIE Fc and wtFc using 
homology modeling. (a) Alignment of the D2 domains of FcγRIIa (PDB 3RY4, yellow), 
FcγRIIb (PDB 2FCB, green), and FcγRIIIa (pink; from the GASDALIE Fc:FcγRIIIa 
complex structure). (b) Sequence alignment of the D1 and D2 domains of FcγRIIa, FcγRIIb 
and FcγRIIIa. Identical residues are highlighted in green and similar residues are highlighted 
in gray. (c–d) Homology modeled interfaces of GASDALIE Fc and wtFc with FcγRIIa and 
FcγRIIb. Predicted electrostatic interactions (red) and hydrogen bonds (yellow) are shown as 
dashes. Residues that are not predicted to participate in the Fc:FcgR interfaces are shown in 
gray. (c) Interactions of chain A of GASDALIE Fc (left) and wtFc (right) with FcγRIIa (top) 
and FcγRIIb (bottom). (d) Interactions of chain B of GASDALIE Fc (left) and wtFc (right) 
with FcγRIIa (top) and FcγRIIb (bottom).
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Figure 4. 
Structure of unbound GASDALIE Fc. (a) Comparison of structures of unbound GASDALIE 
Fc (cyan), SDALIE Fc (blue; PDB 2QL1), and wtFc (gray; PDB IDs: 3DO3, 2DTS, 3AVE, 
4Q7D, 1HZH) after alignment of CH3 domains. (b) Comparison of unbound GASDALIE Fc 
(cyan), FcγRIIIa-bound GASDALIE Fc (blue-gray), and SDALIE Fc (blue) after alignment 
of CH3 domains. (c) wtFc structure (PDB: 3AVE) showing location of Cα atoms for Pro238, 
Phe241, Arg301, and Pro329 (orange spheres) used for CH2 domain separation distance 
measurements. CH2 domain separations in individual Fc structures in Table 2 were 
evaluated by measuring distances (dotted lines) between the corresponding orange spheres 
on each chain. Cα atoms for Asn297 (site of N-glycan attachment) indicated as blue spheres.
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